Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane

a technology of epinastine and nasal mucous membrane, which is applied in the field of treating rhinitis by topically administering aqueous solutions containing epinastine, and can solve the problems of ocular and nasal allergic reactions

Inactive Publication Date: 2005-12-29
BOEHRINGER INGELHEIM INT GMBH
View PDF12 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides solutions that can be applied to the eye and nasal membrane to prevent the influx of certain cells that can cause LPR. These solutions have a longer-lasting effect, reducing the need for frequent applications.

Problems solved by technology

Moreover, ocular and nasal allergic reactions may be due to the release of other mast cell mediators as well as toxic eosinophilic granule proteins and enzymes.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0007] It has been found, surprisingly, that topically administrable aqueous solutions containing epinastine, optionally in the form of its racemate, its enantiomers and possibly in the form of the pharmacologically acceptable acid addition salts thereof, may be used to solve the problem on which the invention is based, since they inhibit the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and nasal mucous membrane, thereby reducing or preventing the occurrence of LPR and are accordingly characterized by a longer lasting duration of activity.

[0008] The compound epinastine (3-amino-9,13b-dihydro-1H-dibenz-[c,f]imidazol[1,5-a]azepine) and the acid addition salts thereof were described for the first time in German Patent Application P 30 08 944.2.

[0009] The effect of the topically administered solutions containing epinastine as inhibitors of the influx of eosinophils and neutrophils was demonstrated using the so-called passive ocular anaphylaxis model ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

A method for treating allergic rhinitis, comprising topically administering to the nasal mucus membrane of a host in need of such treatment a solution comprising: epinastine, optionally in the form of its racemate, its enantiomers, or its pharmacologically acceptable acid addition salts, in a pharmacologically acceptable carrier.

Description

RELATED APPLICATIONS [0001] This application is a continuation of U.S. Ser. No. 10 / 271,180, filed Oct. 15, 2002, which is a continuation of U.S. Ser. No. 09 / 706,650, filed Nov. 6, 2000, now abandoned, which claims priority to German Application No. 199 54 516.2, filed Nov. 12, 1999, and claims benefit of U.S. Provisional Application Ser. No. 60 / 167,771, filed on Nov. 29, 1999, each of which is hereby incorporated by reference.FIELD OF THE INVENTION [0002] The invention relates to topically administered aqueous solutions containing epinastine, optionally in the form of its racemates, its enantiomers, and optionally in the form of the pharmacologically acceptable acid addition salts thereof. BACKGROUND OF THE INVENTION [0003] Allergic reactions of the eye (hereinafter referred to as ocular allergic reactions) signifies a series of differently defined syndromes. The following are examples of ocular allergic reactions, e.g., seasonal allergic conjunctivitis, perennial allergic conjuncti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/08F01L9/20A61K9/00A61K31/55A61P27/02A61P27/16A61P37/08A61P43/00H01F7/18H02K33/04
CPCA61K9/0043Y10S514/912A61K31/55A61K9/0048Y10T137/0318A61P11/00A61P11/02A61P27/00A61P27/02A61P27/14A61P27/16A61P37/08A61P43/00F01L9/20
Inventor TRACH, VOLKERDUSCHLER, GEROLD
Owner BOEHRINGER INGELHEIM INT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com